Evidence map›Paper›PMID 36789695›Full record

ArticleActa biochimica et biophysica Sinica2022

DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.

Hui Huang, Xia Li, Xianlin Zhang, Zhiqiang Li, Duo Han, Wenzhe Gao, Ling Liu, Cheng Peng, Hongwei Zhu, Xiao Yu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hui HuangDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Xia LiDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Xianlin ZhangDepartment of General Surgery, Affiliated Renhe Hospital of China Three Gorges University, Yichang 443001, China.
Zhiqiang LiDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Duo HanDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Wenzhe GaoDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Ling LiuDepartment of Cardiology, Second People's Hospital of Hunan Province, Hunan University of Chinese Medicine, Changsha 410007, China.
Cheng PengDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Hongwei ZhuDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Xiao YuDepartment of Hepatopancreatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome of pancreatic adenocarcinoma (PAAD) patients is poor, given resistance to gemcitabine. Long noncoding RNA (lncRNA) has been implicated in the carcinogenesis of pancreatic cancer; however, its function and mechanism in PAAD resistance to gemcitabine (GEM) are yet unknown. Herein, we demonstrate that lncRNA DSCR9 is significantly reduced in PAAD

Indexed as

AdenocarcinomaImmediate-Early ProteinsMicroRNAsPancreatic NeoplasmsRNA, Long NoncodingApoptosisCell Line, TumorCell MovementCell ProliferationGemcitabineGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceTumor Suppressor ProteinsBTG2 protein, humanGemcitabineImmediate-Early ProteinsMicroRNAsMIRN21 microRNA, humanRNA, Long NoncodingTumor Suppressor ProteinsBTG2gemcitabine resistancelncRNA DSCR9miR-21-5ppancreatic cancerproliferation

Identifiers

PMID36789695
PMCPMC10157615
OpenAlexW4311308018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.